Globeflex Capital L P Acquires Shares of 9,155 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Globeflex Capital L P acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 9,155 shares of the biopharmaceutical company’s stock, valued at approximately $168,000.

A number of other hedge funds have also recently bought and sold shares of ACAD. Natixis Advisors LLC lifted its stake in shares of ACADIA Pharmaceuticals by 16.1% in the 4th quarter. Natixis Advisors LLC now owns 47,007 shares of the biopharmaceutical company’s stock valued at $863,000 after purchasing an additional 6,519 shares during the period. Commonwealth Equity Services LLC lifted its stake in shares of ACADIA Pharmaceuticals by 190.0% in the 4th quarter. Commonwealth Equity Services LLC now owns 43,341 shares of the biopharmaceutical company’s stock valued at $795,000 after purchasing an additional 28,395 shares during the period. Swiss National Bank lifted its stake in shares of ACADIA Pharmaceuticals by 1.4% in the 4th quarter. Swiss National Bank now owns 212,104 shares of the biopharmaceutical company’s stock valued at $3,892,000 after purchasing an additional 2,900 shares during the period. Great Lakes Advisors LLC acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at $9,909,000. Finally, AlphaQuest LLC lifted its stake in shares of ACADIA Pharmaceuticals by 283.8% in the 4th quarter. AlphaQuest LLC now owns 13,511 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 9,991 shares during the period. 96.71% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Elizabeth A. Garofalo sold 4,919 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the transaction, the director now owns 17,595 shares in the company, valued at $320,756.85. This trade represents a 21.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 6,167 shares of company stock worth $114,583 in the last quarter. Corporate insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ ACAD opened at $17.50 on Friday. The stock has a market capitalization of $2.92 billion, a price-to-earnings ratio of 22.44 and a beta of 0.43. The business has a 50-day moving average of $18.40 and a 200-day moving average of $16.98. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $14.15 and a fifty-two week high of $20.68.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Morgan Stanley reissued an “equal weight” rating and issued a $20.00 price target on shares of ACADIA Pharmaceuticals in a research note on Friday, March 7th. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. StockNews.com raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. Guggenheim downgraded ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $23.00 to $20.00 in a research note on Friday, January 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Eight research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $24.00.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.